Dr. Michael Chen, MD
Metabolic Medicine ReviewerDr. Chen completed his medical training at UCSF and fellowship at the Mayo Clinic, specialising in the metabolic underpinnings of obesity and type 2 diabetes. His clinical practice focuses on evidence-based pharmacological and lifestyle interventions for body composition, with particular expertise in GLP-1 agonist protocols, metabolic biomarker interpretation, and continuous glucose monitoring. He joined BiohackingHub as Metabolic Medicine Reviewer in 2025.
Credentials & Qualifications
- MD — University of California San Francisco (UCSF)
- Board Certified: Endocrinology, Diabetes & Metabolism (ABIM)
- Fellowship: Metabolic Syndrome & Obesity Medicine, Mayo Clinic
- Member, Obesity Medicine Association
Selected Publications
Retatrutide and lean mass outcomes: analysis of Phase 2 body composition data
Obesity Reviews·2024
Continuous glucose monitoring in non-diabetic subjects: clinical utility and reference ranges
Journal of Clinical Endocrinology & Metabolism·2023
Recent Reviewed Content
5-Amino-1MQ: Inhibiting NNMT to Prevent Fat Storage and Boost Cellular NAD+
Mar 1, 2026 · Oxford 4
AOD-9604: Targeted Fat Loss Without Insulin Disruption
Mar 1, 2026 · Oxford 2b
Berberine vs. Metformin: The Biohacker's Guide to Blood Sugar Control
Mar 3, 2026 · Oxford 2b
Continuous Glucose Monitors for Biohackers: Stacking Berberine and Diet for Stable Insulin
Mar 5, 2026 · Oxford 2b
MOTS-c: Exercise in a Vial — The Mitochondrial Peptide Changing Metabolic Science
Mar 14, 2026 · Oxford 4
Retatrutide (Triple G): The Future of GLP-1 Agonists in Biohacking
Mar 19, 2026 · Oxford 2b
Specialisations
Member since
February 2025